Saurashtra News

DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including Follicular Lymphoma clinical trials and nonclinical stage products. It also covers the Follicular Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Follicular Lymphoma pipeline products in this space.

In the Follicular Lymphoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Follicular Lymphoma clinical trials studies, Follicular Lymphoma NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Follicular Lymphoma Pipeline Report

• DelveInsight’s Follicular Lymphoma Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Follicular Lymphoma treatment.

• The leading Follicular Lymphoma Companies includes Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, Dr Reddy’s Laboratories, Novartis, ADC Therapeutics, Xynomic Pharmaceuticals, Cho Pharma Inc., Janssen, XEME Biopharma Inc., Shanghai Yingli Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Mabworks Biotech Co., Ltd., Archigen Biotech, Hutchison Medipharma Limited, Nordic Nanovector, Xynomic Pharmaceuticals, TG Therapeutics, BeiGene, Allogene Therapeutics, MEI Pharma, Inc., Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Enterome, AstraZeneca, Nanjing Sanhome Pharmaceutical, Co., Ltd., Takeda, Bristol-Myers Squibb, TCR2 Therapeutics, and others

• Promising Follicular Lymphoma Pipeline Therapies includes DRL_RI (Proposed rituximab biosimilar), GP2013, Venetoclax, Bendamustine, Rituximab, tisagenlecleucel, Obinutuzumab, PF-05280586, Abexinostat, and others.

• The Follicular Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence Follicular Lymphoma R&D. The Follicular Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve Follicular Lymphoma.

To explore more information on the latest breakthroughs in the Follicular Lymphoma Pipeline treatment landscape of the report, click here @ Follicular Lymphoma Pipeline Outlook

Follicular Lymphoma Overview

Follicular lymphoma (FL) is typically a slow-growing or indolent form of non- Hodgkin lymphoma (NHL) that arises from B-lymphocytes, making it a B-cell lymphoma. This lymphoma subtype accounts for 20 to 30 percent of all NHL cases. Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no obvious symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable, but more of a chronic disease. Patients can live for many years with this form of lymphoma. Follicular lymphoma is a B-cell lymphoma. It is characterized by the transformation of a B-cell into a malignant (cancerous) cell. Abnormal, uncontrolled growth and multiplication (proliferation) of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs

Latest Developmental Activities in the Follicular Lymphoma Treatment Landscape

• In October 2021, Novartis received priority review by US FDA and filling acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma.
• Zandelisib is an oral, selective PI3K delta (PI3Kδ) inhibitor being developed to treat follicular lymphoma and other B-cell malignancies. The development and planned commercialisation of zandelisib is being conducted in partnership with Kyowa Kirin Co., Ltd. MEI and KKC will co-develop and co-promote zandelisib in the US, with MEI recording all revenue from US sales. KKC has exclusive commercialisation rights outside of the US.
• In November 2021, US Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to zandelisib to treat follicular lymphoma.
• 5F9 is a monoclonal antibody against CD47 designed to interfere with the recognition of CD47 by the SIRPα receptor on macrophages. In May 2018, 5F9 was granted Fast Track designation by the U.S. Food and Drug Administration to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.
• On November 1, 2021, US Food and Drug Administration has accepted its New Drug Application (NDA) for parsaclisib, an investigational novel potent, highly selective, next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ), for the treatment of patients with relapsed or refractory follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL).
• In July 2020, FDA granted Breakthrough Therapy Designation for Roche’s CD20xCD3 bispecific cancer immunotherapy mosunetuzumab recognising its potential in follicular lymphoma.

For further information, refer to the detailed Follicular Lymphoma Unmet Needs, Follicular Lymphoma Market Drivers, and Follicular Lymphoma Market Barriers, click here for Follicular Lymphoma Ongoing Clinical Trial Analysis

Follicular Lymphoma Emerging Drugs Profile

Mosunetuzumab – Genentech

Mosunetuzumab (Anti-CD20 x CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cell. Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody with monovalent binding to CD20 and monovalent binding to CD3 (1:1 format).The drug is currently in phase 3 stage of development for the treatment of Follicular Lymphoma.

Tafasitamab – Incyte Corporation

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). 

Pembrolizumab: Merck & Co

Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in phase II stage of development to treat Follicular lymphoma.

Zanubrutinib – BeiGene

Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in irreversible inactivation of the enzyme.

Follicular Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Genetech.

Request a sample and discover the recent advances in Follicular Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ Follicular Lymphoma Treatment Landscape

Scope of the Follicular Lymphoma Pipeline Report

• Coverage- Global

• Companies- Merck & Co, Genentech, Incyte Corporation, Syndax Pharmaceuticals, Dr Reddy’s Laboratories, Novartis, ADC Therapeutics, Xynomic Pharmaceuticals, Cho Pharma Inc., Janssen, XEME Biopharma Inc., Shanghai Yingli Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Mabworks Biotech Co., Ltd., Archigen Biotech, Hutchison Medipharma Limited, Nordic Nanovector, Xynomic Pharmaceuticals, TG Therapeutics, BeiGene, Allogene Therapeutics, MEI Pharma, Inc., Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Enterome, AstraZeneca, Nanjing Sanhome Pharmaceutical, Co., Ltd., Takeda, Bristol-Myers Squibb, TCR2 Therapeutics, and others

• Pipeline Therapies- DRL_RI (Proposed rituximab biosimilar), GP2013, Venetoclax, Bendamustine, Rituximab, tisagenlecleucel, Obinutuzumab, PF-05280586, Abexinostat, and others.

• Follicular Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Follicular Lymphoma Market Drivers and Follicular Lymphoma Market Barriers, click here @ Follicular Lymphoma Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Follicular Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mosunetuzumab – Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Pembrolizumab: Merck &Co.
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II) 
14. Drug name: Company name
15. Drug profiles in the detailed report….. Preclinical and Discovery Stage Products 
16. Drug name: Company Name
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Follicular Lymphoma Key Companies
20. Follicular Lymphoma Key Products
21. Follicular Lymphoma- Unmet Needs
22. Follicular Lymphoma- Market Drivers and Barriers
23. Follicular Lymphoma- Future Perspectives and Conclusion
24. Follicular Lymphoma Analyst Views
25. Follicular Lymphoma Key Companies
26. Appendix

Got Queries? Find out the related information on Follicular Lymphoma Mergers and acquisitions, Follicular Lymphoma Licensing Activities @ Follicular Lymphoma Emerging Drugs, and Recent Trends

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services